Targeted therapy of gastrointestinal stromal tumours

Jakhetiya, Ashish; Garg, Pankaj; Prakash, Gaurav; Sharma, Jyoti; Pandey, Rambha; Pandey, Durgatosh

doi:10.4240/wjgs.v8.i5.345

Cited by 35 publications

(34 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mutations in exons 12, 14 and 18 demonstrate variable response to imatinib, sunitib and regorafenib (Jakhetiya et al 2016). Most of the PDGFRA mutations have been identified in exon 18, which is believed to stabilize the kinase activation loop (Dibb et al 2004).…”

Section: Pdgfra-mutated Syndromic Gistsmentioning

confidence: 99%

Classification of gastrointestinal stromal tumor syndromes

Gopie

Faber

et al. 2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, thought to derive from neoplastic outgrowth of the interstitial cells of Cajal. Building on recent advances in recognition, classification and diagnosis, the past two decades have seen a changing paradigm with molecular diagnostics and targeted therapies. KIT and PDGFRA mutations account for 85-90% of GIST carcinogenesis. However, the remaining 10-15% of GISTs, which until recently were called KIT/PDGFRA wild-type GISTs, have been found to have one of the several mutations, including in the SDHA, B, C, D, BRAF and NF1 genes. Though most of such GISTs are sporadic, a number of families with high incidence rates of GISTs and other associated clinical manifestations have been reported and found to harbor germline mutations in KIT, PDGFRA, SDH subunits and NF1. The goal of this review is to describe the mutations, clinical manifestations and therapeutic implications of syndromic and inherited GISTs in light of recent studies of their clinicopathologic range and pathogenesis.

show abstract

Section: Pdgfra-mutated Syndromic Gistsmentioning

confidence: 99%

Classification of gastrointestinal stromal tumor syndromes

Gopie

Faber

et al. 2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…Лечение распространенных и рецидивирующих ГИ-СО ранее представляло собой фактически неразрешимую проблему, поскольку оперативное вмешательство в этом случае не имеет радикального характера, а лучевая тера-пия и стандартные схемы химиотерапии обладают крайне низкой эффективностью [70]. Ситуация изменилась по-сле внедрения в клиническую практику таргетных препа-ратов, в частности иматиниба.…”

Section: архив патологии 4 2017unclassified

Clinical and morphological characteristics of gastrointestinal stromal tumors

Khalikov

Akhmetzyanov²,

Петров³

2017

Arkh. patol.

View full text Add to dashboard Cite

“…Gastrointestinal Stromal Tumours (GISTs) are the most common mesenchymal tumours [ 3 , 4 ]. They constitute 1% to 3% of all malignant gastrointestinal tumours [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)

Ballesteros

Montero

López‐Pousa

et al. 2017

BMC Med Res Methodol

View full text Add to dashboard Cite

BackgroundGastrointestinal Stromal Tumours (GISTs) are the most common mesenchymal tumours. Currently, different pharmacological and surgical options are used to treat localised and metastatic GISTs, although this research field is broad and the body of evidence is scattered and expanding. Our objectives are to identify, describe and organise the current available evidence for GIST through an evidence mapping approach.MethodsWe followed the methodology of Global Evidence Mapping (GEM). We searched Pubmed, EMBASE, The Cochrane Library and Epistemonikos in order to identify systematic reviews (SRs) with or without meta-analyses published between 1990 and March 2016. Two authors assessed eligibility and extracted data. Methodological quality of the included systematic reviews was assessed using AMSTAR. We organised the results according to identified PICO questions and presented the evidence map in tables and a bubble plot.ResultsA total of 17 SRs met eligibility criteria. These reviews included 66 individual studies, of which three quarters were either observational or uncontrolled clinical trials. Overall, the quality of the included SRs was moderate or high. In total, we extracted 14 PICO questions from them and the corresponding results mostly favoured the intervention arm.ConclusionsThe most common type of study used to evaluate therapeutic interventions in GIST sarcomas has been non-experimental studies. However, the majority of the interventions are reported as beneficial or probably beneficial by the respective authors of SRs. The evidence mapping is a useful and reliable methodology to identify and present the existing evidence about therapeutic interventions.Electronic supplementary materialThe online version of this article (doi:10.1186/s12874-017-0402-9) contains supplementary material, which is available to authorized users.

show abstract

Targeted therapy of gastrointestinal stromal tumours

Cited by 35 publications

References 48 publications

Classification of gastrointestinal stromal tumor syndromes

Classification of gastrointestinal stromal tumor syndromes

Clinical and morphological characteristics of gastrointestinal stromal tumors

Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)

Contact Info

Product

Resources

About